History is the best teacher: what can RNA manufacturers learn from the challenges and successes of traditional biologics?

The field of RNA-based vaccines and therapeutics is rapidly evolving. However, despite its reputation for speed and ease, RNA manufacturing can be complex, and looks likely to become even more so as the field evolves. To ensure that manufacturing does not become a bottleneck in bringing new products to market, the industry can learn valuable lessons from the successes and missteps of traditional biologics, including the importance of future proofing and the need for data sharing. On September 27, 2024, Charlotte Barker, Editor, Vaccine Insights, spoke to Adam Brown, Senior Lecturer (Associate Professor), University of Sheffield, about optimizing RNA manufacturing. This article has been written based on that interview.

Please enter your email to access content Read now